NCT03215030 2026-01-29
iinnovate-1
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
Clinical Trials
145 trialsNCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT05172596 2026-01-13
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Novartis
Phase 2 Terminated
NCT04123418 2025-12-24
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Novartis
Phase 1 Terminated
NCT04824794 2025-12-22
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated
NCT03758417 2025-12-17
CARTIFAN-1
Nanjing Legend Biotech Co.
Phase 2 Terminated
NCT06304636 2025-11-24
DC15-MM-01
Cartesian Therapeutics
Phase 1 Terminated
NCT03837509 2025-11-04
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Incyte Corporation
Phase 1/2 Terminated
NCT04582539 2025-10-22
LIMBER
Incyte Corporation
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04702425 2025-10-10
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Novartis
Phase 1 Terminated
NCT03287908 2025-10-08
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Amgen
Phase 1 Terminated
NCT05027594 2025-06-13
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
Nerviano Medical Sciences
Phase 1 Terminated
NCT05839626 2025-06-12
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1/2 Terminated
NCT04318327 2025-05-20
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Novartis
Phase 1 Terminated
NCT04570631 2025-05-16
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Terminated
NCT03994705 2025-05-15
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT04892446 2025-05-02
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 2 Terminated
NCT03486067 2025-04-17
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Terminated
NCT03871829 2025-03-30
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Janssen Research & Development, LLC
Phase 2 Terminated
NCT04975399 2025-03-24
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1 Terminated
NCT06655818 2025-03-03
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Terminated
NCT02761187 2025-02-24
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Takeda
Terminated
NCT03180853 2025-02-03
Multiple Myeloma Patient Registry
Janssen Scientific Affairs, LLC
Terminated
NCT03061305 2025-01-31
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Strata Oncology
Terminated
NCT04887259 2025-01-27
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Lava Therapeutics
Phase 1 Terminated
NCT05427812 2025-01-17
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA
Phase 1/2 Terminated
NCT05113342 2024-11-12
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT05289492 2024-10-26
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
iTeos Therapeutics
Phase 1 Terminated
NCT03755154 2024-10-16
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
Phase 1 Terminated
NCT03710915 2024-10-10
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
HitGen Inc.
Phase 1 Terminated
NCT04816526 2024-10-08
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Cartesian Therapeutics
Phase 2 Terminated
NCT02099539 2024-09-26
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
Phase 1 Terminated
NCT02978235 2024-09-05
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
Phase 1 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT04036461 2024-08-30
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Terminated
NCT04545333 2024-08-01
The clonoSEQ® Watch Registry
Adaptive Biotechnologies
Terminated
NCT05908396 2024-08-01
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
IGM Biosciences, Inc.
Phase 1 Terminated
NCT02400242 2024-07-09
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Celgene
Phase 1 Terminated
NCT02863991 2024-07-03
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
Phase 1/2 Terminated
NCT03777410 2024-07-03
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Travera Inc
Terminated
NCT03448978 2024-07-01
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT05000450 2024-06-28
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics
Phase 1/2 Terminated
NCT01670994 2024-06-18
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
Phase 1/2 Terminated
NCT00775502 2024-04-25
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT02661022 2024-04-17
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Stemline Therapeutics, Inc.
Phase 1/2 Terminated
NCT03288493 2024-03-28
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Poseida Therapeutics, Inc.
Phase 1/2 Terminated
NCT06160609 2024-03-12
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Terminated
NCT05641324 2024-02-12
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Anaveon AG
Phase 1 Terminated
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated